JP2016522254A5 - - Google Patents

Download PDF

Info

Publication number
JP2016522254A5
JP2016522254A5 JP2016521454A JP2016521454A JP2016522254A5 JP 2016522254 A5 JP2016522254 A5 JP 2016522254A5 JP 2016521454 A JP2016521454 A JP 2016521454A JP 2016521454 A JP2016521454 A JP 2016521454A JP 2016522254 A5 JP2016522254 A5 JP 2016522254A5
Authority
JP
Japan
Prior art keywords
compound
och
salt
pharmaceutically acceptable
salt according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016521454A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016522254A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/041825 external-priority patent/WO2014204730A1/en
Publication of JP2016522254A publication Critical patent/JP2016522254A/ja
Publication of JP2016522254A5 publication Critical patent/JP2016522254A5/ja
Pending legal-status Critical Current

Links

JP2016521454A 2013-06-18 2014-06-11 Ｂａｃｅ阻害剤 Pending JP2016522254A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361836175P 2013-06-18 2013-06-18
US61/836,175 2013-06-18
US201361877373P 2013-09-13 2013-09-13
US61/877,373 2013-09-13
PCT/US2014/041825 WO2014204730A1 (en) 2013-06-18 2014-06-11 Bace inhibitors

Publications (2)

Publication Number Publication Date
JP2016522254A JP2016522254A (ja) 2016-07-28
JP2016522254A5 true JP2016522254A5 (enExample) 2016-09-08

Family

ID=51059662

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016521454A Pending JP2016522254A (ja) 2013-06-18 2014-06-11 Ｂａｃｅ阻害剤

Country Status (14)

Country Link
US (2) US9029367B2 (enExample)
EP (1) EP3010925B1 (enExample)
JP (1) JP2016522254A (enExample)
KR (1) KR101780140B1 (enExample)
CN (1) CN105324385A (enExample)
AU (1) AU2014281032B2 (enExample)
BR (1) BR112015029348A8 (enExample)
CA (1) CA2910415C (enExample)
EA (1) EA027880B1 (enExample)
ES (1) ES2657905T3 (enExample)
JO (1) JO3318B1 (enExample)
MX (1) MX2015017156A (enExample)
TW (1) TWI639607B (enExample)
WO (1) WO2014204730A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
AR103680A1 (es) * 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
TW201717948A (zh) 2015-08-10 2017-06-01 Ｈ 朗德貝克公司 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療
JP2018527338A (ja) * 2015-08-12 2018-09-20 ハー・ルンドベック・アクチエゼルスカベット ＢＡＣＥ１阻害剤としての２−アミノ−７ａ−フェニル−３，４，４ａ，５，７，７ａ−ヘキサヒドロフロ［３，４−ｂ］ピリジン
MX2018001699A (es) 2015-08-12 2018-05-07 H Lundbeck As 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidr opiridinas como inhibidores de bace1.
TWI675034B (zh) * 2016-05-20 2019-10-21 美商美國禮來大藥廠 四氫呋喃并<img align="absmiddle" height="18px" width="27px" file="d10999.TIF" alt="其他非圖式 ed10999.png" img-content="tif" orientation="portrait" inline="yes" giffile="ed10999.png"></img>化合物及其作為選擇性ＢＡＣＥ１抑制劑之用途
JP6889466B2 (ja) * 2016-12-09 2021-06-18 学校法人 名城大学 アミド基を含む単離された化合物の塩、その製造方法及びこれを用いたアミド化合物の合成方法
CN107892697B (zh) 2016-12-26 2020-11-03 郑州泰基鸿诺医药股份有限公司 一种[1,3]噻嗪-2-胺类化合物及应用，药物组合物
CN111217709A (zh) * 2018-11-27 2020-06-02 南京药石科技股份有限公司 一种（1-氟环丙基）甲胺盐酸盐的制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG162790A1 (en) 2005-06-14 2010-07-29 Schering Corp Aspartyl protease inhibitors
EP2612854B1 (en) 2005-10-25 2015-04-29 Shionogi&Co., Ltd. Aminothiazolidine and aminotetrahydrothiazepine derivatives as BACE 1 inhibitors
CA2683887A1 (en) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with a cyclic group having inhibitory activity against production of amyloid beta protein
JP5383483B2 (ja) 2007-04-24 2014-01-08 塩野義製薬株式会社 アルツハイマー症治療用医薬組成物
TWI423970B (zh) * 2008-01-18 2014-01-21 衛材Ｒ＆Ｄ企管股份有限公司 經稠合之胺基二氫噻衍生物
TWI431004B (zh) * 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
JP5490692B2 (ja) 2008-06-13 2014-05-14 塩野義製薬株式会社 βセクレターゼ阻害作用を有する含硫黄複素環誘導体
US20110207723A1 (en) 2008-09-30 2011-08-25 Eisai R&D Management Co., Ltd. Novel fused aminodihydrothiazine derivative
AR077277A1 (es) * 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
US20120245154A1 (en) 2009-12-09 2012-09-27 Shionogi & Co., Ltd. Substituted aminothiazine derivative
UA103272C2 (uk) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
JPWO2011071135A1 (ja) 2009-12-11 2013-04-22 塩野義製薬株式会社 オキサジン誘導体
EP2511269A4 (en) 2009-12-11 2013-04-24 Shionogi & Co FUSED HETEROCYCLIC COMPOUND HAVING AN AMINO GROUP
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
SG10201601516QA (en) 2011-01-21 2016-03-30 Eisai R&D Man Co Ltd Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
WO2012138590A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US8754075B2 (en) 2011-04-11 2014-06-17 Hoffmann-La Roche Inc. 1,3-oxazines as BACE1 and/or BACE2 inhibitors
US8785436B2 (en) 2011-05-16 2014-07-22 Hoffmann-La Roche Inc. 1,3-oxazines as BACE 1 and/or BACE2 inhibitors
US8598161B2 (en) 2011-05-24 2013-12-03 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
BR112013031510A2 (pt) 2011-06-07 2016-12-27 Hoffmann La Roche [1,3]oxazinas
UY34278A (es) 2011-08-25 2013-04-05 Novartis Ag Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
WO2013030713A1 (en) 2011-08-31 2013-03-07 Pfizer Inc. Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds
LT3421470T (lt) 2011-11-25 2021-04-26 Adverio Pharma Gmbh Pakeistieji 5-fluor-1h-pirazolopiridinai kristalų pavidale
JP6118817B2 (ja) 2012-04-27 2017-04-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 ５−（ジフルオロメチル）ピラジン−２−カルボン酸の製造方法およびその製造中間体
ES2585262T3 (es) 2012-05-04 2016-10-04 Pfizer Inc Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
WO2014015125A1 (en) 2012-07-19 2014-01-23 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivative salts and uses thereof
GB201212871D0 (en) 2012-07-20 2012-09-05 Eisai Ltd Novel compounds

Similar Documents

Publication Publication Date Title
JP2016522254A5 (enExample)
JP2016106149A5 (enExample)
JP2016518437A5 (enExample)
JP2013519675A5 (enExample)
JP2018021051A5 (enExample)
JP2019524883A5 (enExample)
JP2015522589A5 (enExample)
JP2016536286A5 (enExample)
JP2016534063A5 (enExample)
JP2015024998A5 (enExample)
RU2017112747A (ru) Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции
JP2013537203A5 (enExample)
JP2016525102A5 (enExample)
JP2016518328A5 (enExample)
JP2019516739A5 (enExample)
JP2016513130A5 (enExample)
RU2017105353A (ru) Соединения
JP2016505637A5 (enExample)
JP2016510326A5 (enExample)
JP2017522300A5 (enExample)
JP2019505529A5 (enExample)
JP2016539157A5 (enExample)
JP2016523260A5 (enExample)
JP2017511377A5 (enExample)
JP2015516419A5 (enExample)